Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) (NCT05853367)

🧪 Interventions in This Study

• MK-0472 (DRUG)
• Pembrolizumab (BIOLOGICAL)
• MK-1084 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (25 Sites)

• Northwestern Memorial Hospital ( Site 0002) — Chicago, Illinois
• The University of Louisville, James Graham Brown Cancer Center ( Site 0004) — Louisville, Kentucky
• John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) — Hackensack, New Jersey
• Rutgers Cancer Institute of New Jersey ( Site 0005) — New Brunswick, New Jersey
• Princess Margaret Cancer Centre ( Site 0101) — Toronto, Ontario
• Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100) — Montreal, Quebec
• Département clinique de médecine de laboratoire du CHUM ( Site 0104) — Montreal, Quebec
• Centro de Estudios Clínicos SAGA ( Site 0701) — Santiago, Region M. de Santiago
• Fundacion Arturo Lopez Perez ( Site 0700) — Santiago, Region M. de Santiago
• Centro de Investigacion Clinicadela Universidad Catolica ( Site 0703) — Santiago, Region M. de Santiago
• Bradfordhill ( Site 0702) — Santiago, Region M. de Santiago
• Rambam Health Care Campus ( Site 0304) — Haifa,
• Shaare Zedek Medical Center ( Site 0303) — Jerusalem,
• Rabin Medical Center ( Site 0301) — Petah Tikva,
• Sheba Medical Center ( Site 0300) — Ramat Gan,
• Sourasky Medical Center ( Site 0302) — Tel Aviv,
• Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0401) — Warsaw, Masovian Voivodeship
• Uniwersyteckie Centrum Kliniczne ( Site 0400) — Gdansk, Pomeranian Voivodeship
• Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 0501) — L'Hospitalet de Llobregat, Catalonia
• Centro Integral Oncologico Clara Campal-Hospital HM Universitario Sanchinarro-START Madrid, ( Site 0504) — Madrid, Madrid, Comunidad de
• Hospital Universitari Vall d'Hebron ( Site 0500) — Barcelona,
• Hospital Virgen del Rocio ( Site 0503) — Seville,
• Hôpitaux Universitaires de Genève (HUG) ( Site 0202) — Geneva, Canton of Geneva
• Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201) — Sankt Gallen, Canton of St. Gallen
• Ospedale Regionale Bellinzona e Valli ( Site 0200) — Bellinzona, Canton Ticino

📞 Contact the Study Coordinator

Phone: (855) 692-6482

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Solid Tumors

• SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors — Newport Beach, California
• A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors — Santa Rosa, California
• The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. — Rochester, Minnesota
• A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. — Nashville, Tennessee
• SLV-324 Treatment of Metastatic Solid Tumors — Newport Beach, California

Explore by condition: All Metastatic Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.